Correlation Between Cadrenal Therapeutics, and Transcode Therapeutics

Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and Transcode Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and Transcode Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cadrenal Therapeutics, Common and Transcode Therapeutics, you can compare the effects of market volatilities on Cadrenal Therapeutics, and Transcode Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of Transcode Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and Transcode Therapeutics.

Diversification Opportunities for Cadrenal Therapeutics, and Transcode Therapeutics

-0.03

Correlation Coefficient

Cadrenal Therapeutics,  Transcode Therapeutics

Good diversification

The 3 months correlation between Cadrenal and Transcode is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and Transcode Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Transcode Therapeutics and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with Transcode Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Transcode Therapeutics has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and Transcode Therapeutics go up and down completely randomly.

Pair Corralation between Cadrenal Therapeutics, and Transcode Therapeutics

Given the investment horizon of 90 days Cadrenal Therapeutics, Common is expected to under-perform the Transcode Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Cadrenal Therapeutics, Common is 1.55 times less risky than Transcode Therapeutics. The stock trades about -0.12 of its potential returns per unit of risk. The Transcode Therapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  1,434  in Transcode Therapeutics on May 2, 2025 and sell it today you would lose (339.00) from holding Transcode Therapeutics or give up 23.64% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Cadrenal Therapeutics, Common  vs.  Transcode Therapeutics

Cadrenal Therapeutics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cadrenal Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward-looking signals remain rather sound which may send shares a bit higher in August 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Transcode Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Transcode Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest inconsistent performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Cadrenal Therapeutics, and Transcode Therapeutics

The main advantage of trading using opposite Cadrenal Therapeutics, and Transcode Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, Transcode Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Transcode Therapeutics will offset losses from the drop in Transcode Therapeutics' long position.

The idea behind Cadrenal Therapeutics, Common and Transcode Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.